News 2025
17.10.2025
Joint meeting: Northern Germany Meeting on Infection, Immunology & Inflammation
On Wednesday, October 8, 125 researchers from across Northern Germany gathered for the first Northern Germany Meeting on Infection, Immunology & Inflammation at Research Centre Borstel’s Manor House. The meeting was co-organized and co-hosted by “New Developments in Immunology, Inflammation, & Infection” (NDI³) – i.e. twelve PhD students from the FZB – and the NordInfect initiative.
14.10.2025
Bewilligung eines dauerhaften Sondertatbestands sichert Betrieb neuer Forschungsgebäude
Mit der Bewilligung eines dauerhaften nicht-strategischen Sondertatbestands (Kategorie B2) erhält das Forschungszentrum Borstel, Leibniz Lungenzentrum (FZB) eine wichtige finanzielle Unterstützung zur Sicherung des nachhaltigen Betriebs seiner Forschungsinfrastruktur. Der Beschluss des Ausschusses der Gemeinsamen Wissenschaftskonferenz von Bund und Ländern (GWK) stellt sicher, dass die zusätzlichen Betriebskosten für die beiden neuen und hochmodernen Forschungsgebäude - dem Leibniz-Respiratorium (LRB) und dem Nationalen Referenzzentrum für Mykobakteriologie (NRZ) - langfristig gedeckt werden können.
02.10.2025
Tuberculosis and Migration: Protecting the Most Vulnerable
Tuberculosis (TB) remains one of the world’s most dangerous infectious diseases – and it affects people on the move particularly hard. In Germany, nearly three out of four TB cases are found in people who were not born in the country. How migration, poverty, and war are shaping the spread of TB in Europe was the focus of a symposium organized by the Research Center Borstel, Leibniz Lung Center (FZB), at the 14th Congress for Tropical Medicine and International Health in Hamburg. The Symposium was chaired by Dr. Thomas Brehm and Prof. Christoph Lange (both FZB and UKE, Hamburg).
01.10.2025
Antibiotic resistance can also make bacteria more vulnerable
Antibiotic resistance is one of the greatest challenges in modern medicine. A new study now shows that Haemophilus influenzae can rapidly adapt to commonly used beta-lactam antibiotics. However, the genetic changes and their consequences are surprisingly diverse and difficult to predict. Some mutations even make the bacteria more susceptible to other drugs.